Resmed Inc (RMD) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ResMed is launching a new clinical trial called “Evaluation of a Novel Wearable Device for Circadian Rhythm Monitoring in Healthy, OSA, and Insomnia Participants.” The study aims to test how practical and accurate a new wearable is at tracking daily body rhythm patterns, which matter for sleep, daytime alertness, and the broader sleep health market.
The trial tests a single wearable device designed to track body signals continuously and non invasively. The goal is to estimate circadian rhythm and compare those readings to melatonin levels, which are a common benchmark for internal clock timing.
This is an interventional study but uses only one group of participants who all receive the same device. There is no random assignment or placebo, and no blinding, so the focus is on feasibility and device performance rather than direct health outcomes or head to head treatment comparisons.
The study is listed as “Not yet recruiting,” signaling that enrollment has not started. It was first submitted on 1 January 2026, with the latest update on 17 May 2026, so investors should view it as an early stage validation step with data readouts likely some time after recruitment begins.
For investors, this trial highlights ResMed’s push into circadian and broader wearable monitoring, beyond traditional CPAP and respiratory devices. Success here could support new data services, reinforce its ecosystem against rivals in sleep tech and consumer wearables, and improve sentiment if the device proves accurate and easy to use.
The update also underscores competition with both medical device peers and large consumer players that are adding sleep and circadian features. Any positive results may not move revenue in the near term but could strengthen the long term story around digital sleep health and integrated care platforms for RMD shareholders.
The study remains in the startup phase with status “Not yet recruiting,” and investors can track future changes and details as they appear on the ClinicalTrials portal.